Skip to main content
Erschienen in: Current Neurology and Neuroscience Reports 7/2018

01.07.2018 | Demyelinating Disorders (J Bernard and M Cameron, Section Editors)

Behçet’s Syndrome and Nervous System Involvement

verfasst von: Uğur Uygunoğlu, Aksel Siva

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Although Behçet’s syndrome (BS) is classified as a rare disease in European countries and the USA, its neurologic involvement “neuro-Behçet’s syndrome (NBS)” is commonly included in the differential diagnosis of many inflammatory and vascular central nervous system (CNS) disorders. Clinical and neuroimaging findings support two major forms of NBS: parenchymal NBS (p-NBS) and an extra-parenchymal form that presents with cerebral venous sinus thrombosis (CVST). The present review summarizes recent findings on the etiopathogenesis and clinico-radiological features of this disorder as well as its treatment options.

Recent Findings

Recent laboratory and clinical findings include the discovery of antibodies to human and mouse neuro-fibrils showing cross-reactivity with Streptococcus spp. and Mycobacterium tuberculosis heat shock proteins (HSP) in NBS. Diagnostically, two distinct magnetic resonance imaging (MRI) patterns of spinal cord involvement have been observed: (a) “Bagel sign” and (b) “motor neuron” patterns. Therapeutic studies have shown that infliximab effectively prevents further relapses and stabilizes the symptoms of patients experiencing ongoing clinical relapses while being treated with single or multiple immunosuppressant drugs.

Summary

Primary neurological involvement referred to as NBS. The majority of patients with NBS present with parenchymal involvement that commonly affects the brain stem-diencephalic region. Headache, dysarthria, ataxia, and hemiparesis are the main clinical features of NBS.
Literatur
2.
Zurück zum Zitat International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet 1990; 335, 1078–1080. International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet 1990; 335, 1078–1080.
3.
Zurück zum Zitat •• Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14(2):107–19. This comprehensive review discuss the concept of Behçet syndrome together with the clinical, laboratory features and treatment options. CrossRefPubMed •• Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14(2):107–19. This comprehensive review discuss the concept of Behçet syndrome together with the clinical, laboratory features and treatment options. CrossRefPubMed
4.
Zurück zum Zitat Yazıcı H, Fresko I, Yurdakul S. Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007;3:151–5.CrossRef Yazıcı H, Fresko I, Yurdakul S. Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007;3:151–5.CrossRef
5.
Zurück zum Zitat Yurdakul S, Gunaydin I, Tuzun Y, et al. The prevalence of Behcet’s syndrome in a rural area in northern Turkey. J Rheumatol. 1988;15(5):820–2.PubMed Yurdakul S, Gunaydin I, Tuzun Y, et al. The prevalence of Behcet’s syndrome in a rural area in northern Turkey. J Rheumatol. 1988;15(5):820–2.PubMed
6.
Zurück zum Zitat Azizlerli G, Köse AA, Sarica R, Gül A, Tutkun IT, Kulaç M, et al. Prevalence of Behcet’s disease in Istanbul, Turkey. Int J Dermatol. 2003;42(10):803–6.CrossRefPubMed Azizlerli G, Köse AA, Sarica R, Gül A, Tutkun IT, Kulaç M, et al. Prevalence of Behcet’s disease in Istanbul, Turkey. Int J Dermatol. 2003;42(10):803–6.CrossRefPubMed
7.
Zurück zum Zitat Zouboulis CC, Kötter I, Djawari D, Kirch W, Kohl PK, Ochsendorf FR, et al. Epidemiological features of Adamantiades-Behçet’s disease in Germany and in Europe. Yonsei Med J. 1997;38:411–22.CrossRefPubMed Zouboulis CC, Kötter I, Djawari D, Kirch W, Kohl PK, Ochsendorf FR, et al. Epidemiological features of Adamantiades-Behçet’s disease in Germany and in Europe. Yonsei Med J. 1997;38:411–22.CrossRefPubMed
8.
9.
Zurück zum Zitat Mahr A, Belarbi L, Wechsler B, Jeanneret D, Dhote R, Fain O, et al. Population-based prevalence study of Behçet’s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 2008;58(12):3951–9.CrossRefPubMed Mahr A, Belarbi L, Wechsler B, Jeanneret D, Dhote R, Fain O, et al. Population-based prevalence study of Behçet’s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 2008;58(12):3951–9.CrossRefPubMed
10.
Zurück zum Zitat • Leccese P, Yazici Y, Olivieri I. Behcet’s syndrome in nonendemic regions. Curr Opin Rheumatol. 2017;29(1):12–6. This paper points out the increased prevalence of BS in non-endemic regions due to immigration from endemic countries. CrossRefPubMed • Leccese P, Yazici Y, Olivieri I. Behcet’s syndrome in nonendemic regions. Curr Opin Rheumatol. 2017;29(1):12–6. This paper points out the increased prevalence of BS in non-endemic regions due to immigration from endemic countries. CrossRefPubMed
11.
Zurück zum Zitat Ozdoğan H. Behçet’s syndrome in children. Rheumatol Eur. 1994;23(Suppl 12):34. Ozdoğan H. Behçet’s syndrome in children. Rheumatol Eur. 1994;23(Suppl 12):34.
12.
Zurück zum Zitat Yurdakul S, Yazici H. Behcet’s syndrome. Best Pract Res Clin Rheumatol. 2008;22(5):793–809.CrossRefPubMed Yurdakul S, Yazici H. Behcet’s syndrome. Best Pract Res Clin Rheumatol. 2008;22(5):793–809.CrossRefPubMed
13.
Zurück zum Zitat Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60–76.CrossRef Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60–76.CrossRef
14.
Zurück zum Zitat Hatemi I, Esatoglu SN, Hatemi G, Erzin Y, Yazici H, Celik AF. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet’s syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore). 2016;95(16):e3348.CrossRef Hatemi I, Esatoglu SN, Hatemi G, Erzin Y, Yazici H, Celik AF. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet’s syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore). 2016;95(16):e3348.CrossRef
15.
Zurück zum Zitat Direskeneli H. Autoimmunity vs autoinflammation in Behcet’s disease: do we oversimplify a complex disorder? Rheumatology (Oxford). 2006;45(12):1461–5.CrossRef Direskeneli H. Autoimmunity vs autoinflammation in Behcet’s disease: do we oversimplify a complex disorder? Rheumatology (Oxford). 2006;45(12):1461–5.CrossRef
16.
Zurück zum Zitat Gul A. Behcet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy. 2005;4:81–3.CrossRefPubMed Gul A. Behcet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy. 2005;4:81–3.CrossRefPubMed
17.
Zurück zum Zitat • Lule S, Colpak AI, Balci-Peynircioglu B, Gursoy-Ozdemir Y, Peker S, Kalyoncu U, et al. Behçet disease serum is immunoreactive to neurofilament medium which share common epitopes to bacterial HSP-65, a putative trigger. J Autoimmun. 2017;84:87–96. The authors found a new antigen showing cross reactivity with the bacterial protein HSP-65 supporting the autoimmune disease theory in BS. CrossRefPubMed • Lule S, Colpak AI, Balci-Peynircioglu B, Gursoy-Ozdemir Y, Peker S, Kalyoncu U, et al. Behçet disease serum is immunoreactive to neurofilament medium which share common epitopes to bacterial HSP-65, a putative trigger. J Autoimmun. 2017;84:87–96. The authors found a new antigen showing cross reactivity with the bacterial protein HSP-65 supporting the autoimmune disease theory in BS. CrossRefPubMed
18.
Zurück zum Zitat Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012;51(5):887–900.CrossRef Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012;51(5):887–900.CrossRef
19.
Zurück zum Zitat McGonagle D, Aydin SZ, Gül A, Mahr A, Direskeneli H. “MHC-I-opathy”—unified concept for spondyloarthritis and Behçet disease. Nat Rev Rheumatol. 2015;11(12):731–40.CrossRefPubMed McGonagle D, Aydin SZ, Gül A, Mahr A, Direskeneli H. “MHC-I-opathy”—unified concept for spondyloarthritis and Behçet disease. Nat Rev Rheumatol. 2015;11(12):731–40.CrossRefPubMed
20.
Zurück zum Zitat Yazici H. Behçet’s syndrome in the 2000s: “where is the wisdom we have lost in knowledge?”. Clin Exp Rheumatol. 2016;34(6 Suppl 102):23–5.PubMed Yazici H. Behçet’s syndrome in the 2000s: “where is the wisdom we have lost in knowledge?”. Clin Exp Rheumatol. 2016;34(6 Suppl 102):23–5.PubMed
21.
22.
Zurück zum Zitat Demirkesen C, Öz B, Göksel S. Behçet’s disease: pathology. In: Yazıcı Y, Yazıcı H, editors. Behçet’s syndrome. Berlin: Springer; 2010. p. 215–41.CrossRef Demirkesen C, Öz B, Göksel S. Behçet’s disease: pathology. In: Yazıcı Y, Yazıcı H, editors. Behçet’s syndrome. Berlin: Springer; 2010. p. 215–41.CrossRef
23.
Zurück zum Zitat Hatemi G, Yazici Y, Yazici H. Behçet’s syndrome. Rheum Dis Clin N Am. 2013;39(2):245–61.CrossRef Hatemi G, Yazici Y, Yazici H. Behçet’s syndrome. Rheum Dis Clin N Am. 2013;39(2):245–61.CrossRef
24.
Zurück zum Zitat Rogers RS 3rd. Recurrent aphthous stomatitis in the diagnosis of Behcet’s disease. Yonsei Med J. 1997;38(6):370–9.CrossRefPubMed Rogers RS 3rd. Recurrent aphthous stomatitis in the diagnosis of Behcet’s disease. Yonsei Med J. 1997;38(6):370–9.CrossRefPubMed
25.
Zurück zum Zitat Esatoglu SN, Kutlubay Z, Ucar D, Hatemi I, Uygunoglu U, Siva A, et al. Behçet’s syndrome: providing integrated care. J Multidiscip Healthc. 2017;10:309–19.CrossRefPubMedPubMedCentral Esatoglu SN, Kutlubay Z, Ucar D, Hatemi I, Uygunoglu U, Siva A, et al. Behçet’s syndrome: providing integrated care. J Multidiscip Healthc. 2017;10:309–19.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Mat MC, Goksugur N, Engin B, Yurdakul S, Yazici H. The frequency of scarring after genital ulcers in Behcet’s syndrome: a prospective study. Int J Dermatol. 2006;45(5):554–6.CrossRefPubMed Mat MC, Goksugur N, Engin B, Yurdakul S, Yazici H. The frequency of scarring after genital ulcers in Behcet’s syndrome: a prospective study. Int J Dermatol. 2006;45(5):554–6.CrossRefPubMed
27.
Zurück zum Zitat The International Study Group for Behçet’s Disease. Evaluation of diagnostic (‘classification’) criteria in Behçet’s disease—towards internationally agreed criteria. Br J Rheumatol. 1992;31:299–308.CrossRef The International Study Group for Behçet’s Disease. Evaluation of diagnostic (‘classification’) criteria in Behçet’s disease—towards internationally agreed criteria. Br J Rheumatol. 1992;31:299–308.CrossRef
28.
29.
Zurück zum Zitat Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H. Ocular features of Behcet’s disease: an international collaborative study. Br J Ophthalmol. 2007;91(12):1579–82.CrossRefPubMedPubMedCentral Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H. Ocular features of Behcet’s disease: an international collaborative study. Br J Ophthalmol. 2007;91(12):1579–82.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Cingu AK, Onal S, Urgancioglu M, Tugal-Tutkun I. Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm. 2012;20(6):423–8.CrossRefPubMed Cingu AK, Onal S, Urgancioglu M, Tugal-Tutkun I. Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm. 2012;20(6):423–8.CrossRefPubMed
31.
Zurück zum Zitat Tugal-Tutkun I, Ozdal PC, Oray M, Onal S. Review for diagnostics of the year: multimodal imaging in Behçet uveitis. Ocul Immunol Inflamm. 2017;25(1):7–19.CrossRefPubMed Tugal-Tutkun I, Ozdal PC, Oray M, Onal S. Review for diagnostics of the year: multimodal imaging in Behçet uveitis. Ocul Immunol Inflamm. 2017;25(1):7–19.CrossRefPubMed
32.
Zurück zum Zitat Hatemi I, Hatemi G, Çelik AF. Gastrointestinal involvement in Behçet disease. Rheum Dis Clin N Am. 2018;44(1):45–64.CrossRef Hatemi I, Hatemi G, Çelik AF. Gastrointestinal involvement in Behçet disease. Rheum Dis Clin N Am. 2018;44(1):45–64.CrossRef
33.
Zurück zum Zitat Bicer A. Musculoskeletal findings in Behcet’s disease. Pathol Res Int. 2012;2012:653806.CrossRef Bicer A. Musculoskeletal findings in Behcet’s disease. Pathol Res Int. 2012;2012:653806.CrossRef
34.
Zurück zum Zitat Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H. Vascular involvement in Behçet’s syndrome: a retrospective analysis of associations and the time course. Rheumatology (Oxford). 2014;53(11):2018–22.CrossRef Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H. Vascular involvement in Behçet’s syndrome: a retrospective analysis of associations and the time course. Rheumatology (Oxford). 2014;53(11):2018–22.CrossRef
35.
Zurück zum Zitat Marzban M, Mandegar MH, Karimi A, Abbasi K, Movahedi N, Navabi MA, et al. Cardiac and great vessel involvement in “Behcet’s disease”. J Card Surg. 2008;23(6):765–8.CrossRefPubMed Marzban M, Mandegar MH, Karimi A, Abbasi K, Movahedi N, Navabi MA, et al. Cardiac and great vessel involvement in “Behcet’s disease”. J Card Surg. 2008;23(6):765–8.CrossRefPubMed
36.
Zurück zum Zitat Seyahi E, Melikoglu M, Akman C, Hamuryudan V, Ozer H, Hatemi G, et al. Pulmonary artery involvement and associated lung disease in Behcet disease: a series of 47 patients. Medicine (Baltimore). 2012;91(1):35–48.CrossRef Seyahi E, Melikoglu M, Akman C, Hamuryudan V, Ozer H, Hatemi G, et al. Pulmonary artery involvement and associated lung disease in Behcet disease: a series of 47 patients. Medicine (Baltimore). 2012;91(1):35–48.CrossRef
37.
Zurück zum Zitat •• Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, et al. Diagnosis and management of neuro-Behçet’s disease: international consensus recommendations. J Neurol. 2014;261(9):1662–76. This study reports international consensus recommendations for NBS diagnosis. CrossRefPubMed •• Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, et al. Diagnosis and management of neuro-Behçet’s disease: international consensus recommendations. J Neurol. 2014;261(9):1662–76. This study reports international consensus recommendations for NBS diagnosis. CrossRefPubMed
38.
Zurück zum Zitat Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, et al. Behçet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol. 2001;248(2):95–103.CrossRefPubMed Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, et al. Behçet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol. 2001;248(2):95–103.CrossRefPubMed
39.
Zurück zum Zitat Siva A, Saip S. The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis. J Neurol. 2009;256(4):513–29.CrossRefPubMed Siva A, Saip S. The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis. J Neurol. 2009;256(4):513–29.CrossRefPubMed
40.
Zurück zum Zitat Siva A. Common clinical and imaging conditions misdiagnosed as multiple sclerosis: A Current Approach to the Differential Diagnosis of Multiple Sclerosis. Neurol Clin. 2018;36(1):69–117.CrossRefPubMed Siva A. Common clinical and imaging conditions misdiagnosed as multiple sclerosis: A Current Approach to the Differential Diagnosis of Multiple Sclerosis. Neurol Clin. 2018;36(1):69–117.CrossRefPubMed
41.
Zurück zum Zitat Uluduz D, Kürtüncü M, Yapıcı Z, Seyahi E, Kasapçopur Ö, Özdoğan H, et al. Clinical characteristics of pediatric-onset neuro-Behcet disease. Neurology. 2011;77(21):1900–5.CrossRefPubMed Uluduz D, Kürtüncü M, Yapıcı Z, Seyahi E, Kasapçopur Ö, Özdoğan H, et al. Clinical characteristics of pediatric-onset neuro-Behcet disease. Neurology. 2011;77(21):1900–5.CrossRefPubMed
42.
Zurück zum Zitat Saip S, Siva A, Altintas A, Kiyat A, Seyahi E, Hamuryudan V, et al. Headache in Behcet’s syndrome. Headache. 2005;45:911–9.CrossRefPubMed Saip S, Siva A, Altintas A, Kiyat A, Seyahi E, Hamuryudan V, et al. Headache in Behcet’s syndrome. Headache. 2005;45:911–9.CrossRefPubMed
43.
Zurück zum Zitat Baykan B, Ertas M, Karlı N, Uluduz D, Uygunoglu U, Ekizoglu E, et al. Migraine incidence in 5 years: a population-based prospective longitudinal study in Turkey. J Headache Pain. 2015;16:103.CrossRefPubMedPubMedCentral Baykan B, Ertas M, Karlı N, Uluduz D, Uygunoglu U, Ekizoglu E, et al. Migraine incidence in 5 years: a population-based prospective longitudinal study in Turkey. J Headache Pain. 2015;16:103.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Siva A, Özdoğan H, Yazıcı H, Yurdakul S, Yardım M, Akyatan N, et al. Headache, neuro-psychiatric and computerized tomography findings in Behçet’s syndrome. In: Lehner T, Barnes CG, editors. Recent advances in Behçet’s disease. London: Royal Society of Medicine Service; 1986. p. 247–54. Siva A, Özdoğan H, Yazıcı H, Yurdakul S, Yardım M, Akyatan N, et al. Headache, neuro-psychiatric and computerized tomography findings in Behçet’s syndrome. In: Lehner T, Barnes CG, editors. Recent advances in Behçet’s disease. London: Royal Society of Medicine Service; 1986. p. 247–54.
45.
Zurück zum Zitat Keskin Y, Seyahi E, Poyraz C, Ugurlu S, Ozyazgan Y, Yazici H. Interferon alfa-associated depression in patients with Behçet’s syndrome: a prospective controlled study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S175.PubMed Keskin Y, Seyahi E, Poyraz C, Ugurlu S, Ozyazgan Y, Yazici H. Interferon alfa-associated depression in patients with Behçet’s syndrome: a prospective controlled study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S175.PubMed
46.
Zurück zum Zitat Uygunoğlu U, Benbir G, Saip S, Kaynak H, Siva A. A polysomnographic and clinical study of sleep disorders in patients with Behçet and neuro-Behçet syndrome. Eur Neurol. 2014;71(3–4):115–9.CrossRefPubMed Uygunoğlu U, Benbir G, Saip S, Kaynak H, Siva A. A polysomnographic and clinical study of sleep disorders in patients with Behçet and neuro-Behçet syndrome. Eur Neurol. 2014;71(3–4):115–9.CrossRefPubMed
47.
Zurück zum Zitat Gündüz T, Emir Ö, Kürtüncü M, Mutlu M, Tumaç A, Akca S, et al. Cognitive impairment in neuro-Behcet’s disease and multiple sclerosis: a comparative study. Int J Neurosci. 2012;122(11):650–6.CrossRefPubMed Gündüz T, Emir Ö, Kürtüncü M, Mutlu M, Tumaç A, Akca S, et al. Cognitive impairment in neuro-Behcet’s disease and multiple sclerosis: a comparative study. Int J Neurosci. 2012;122(11):650–6.CrossRefPubMed
48.
Zurück zum Zitat Uygunoglu U, Saip S, Siva A. Behcet’s syndrome and nervous system involvement. In: Lisak RP, Truong DD, Carroll WM, et al., editors. International neurology, vol. 2016. 2nd ed. Chichester: John Wiley & Sons, Ltd. p. 88–93. Chapter 28. Uygunoglu U, Saip S, Siva A. Behcet’s syndrome and nervous system involvement. In: Lisak RP, Truong DD, Carroll WM, et al., editors. International neurology, vol. 2016. 2nd ed. Chichester: John Wiley & Sons, Ltd. p. 88–93. Chapter 28.
49.
Zurück zum Zitat Alkan A, Goktan A, Karincaoglu Y, Kamisli S, Dogan M, Oztanir N, et al. Brain perfusion MRI findings in patients with Behcet’s disease. Sci World J. 2012;2012:261502.CrossRef Alkan A, Goktan A, Karincaoglu Y, Kamisli S, Dogan M, Oztanir N, et al. Brain perfusion MRI findings in patients with Behcet’s disease. Sci World J. 2012;2012:261502.CrossRef
50.
Zurück zum Zitat Chuang YW, Hsu CC, Huang YF, Lin HF, Chang CC, Lin CY, et al. Brain perfusion SPECT in patients with Behçet’s disease. J Neuroradiol. 2013;40(4):288–93.CrossRefPubMed Chuang YW, Hsu CC, Huang YF, Lin HF, Chang CC, Lin CY, et al. Brain perfusion SPECT in patients with Behçet’s disease. J Neuroradiol. 2013;40(4):288–93.CrossRefPubMed
51.
Zurück zum Zitat Saip S, Akman-Demir G, Siva A. Neuro-Behçet syndrome. Handb Clin Neurol. 2014;121:1703–23.CrossRefPubMed Saip S, Akman-Demir G, Siva A. Neuro-Behçet syndrome. Handb Clin Neurol. 2014;121:1703–23.CrossRefPubMed
52.
Zurück zum Zitat Akman-Demir G, Serdaroglu P, Tasçi B. Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The neuro-Behçet study group. Brain. 1999;122(Pt 11):2171–82.CrossRefPubMed Akman-Demir G, Serdaroglu P, Tasçi B. Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The neuro-Behçet study group. Brain. 1999;122(Pt 11):2171–82.CrossRefPubMed
53.
Zurück zum Zitat Ishido M, Horita N, Takeuchi M, Shibuya E, Yamane T, Kawagoe T, et al. Distinct clinical features between acute and chronic progressive parenchymal neuro-Behçet disease: meta-analysis. Sci Rep. 2017;7(1):10196.CrossRefPubMedPubMedCentral Ishido M, Horita N, Takeuchi M, Shibuya E, Yamane T, Kawagoe T, et al. Distinct clinical features between acute and chronic progressive parenchymal neuro-Behçet disease: meta-analysis. Sci Rep. 2017;7(1):10196.CrossRefPubMedPubMedCentral
54.
Zurück zum Zitat Kocer N, Islak C, Siva A, et al. CNS involvement in neuro-Behcet’s syndrome: an MR study. AJNR Am J Neuroradiol. 1999;20:1015–24.PubMed Kocer N, Islak C, Siva A, et al. CNS involvement in neuro-Behcet’s syndrome: an MR study. AJNR Am J Neuroradiol. 1999;20:1015–24.PubMed
55.
Zurück zum Zitat Cohen-Aubart F, Psimaras D, Galanaud D, Bielle F, Touitou V, Haroche J, et al. Cerebral pseudo-tumoral neuro-Behcet: histological demonstration of an inflammatory and vascular disease. Clin Neurol Neurosurg. 2017;161:48–50.CrossRefPubMed Cohen-Aubart F, Psimaras D, Galanaud D, Bielle F, Touitou V, Haroche J, et al. Cerebral pseudo-tumoral neuro-Behcet: histological demonstration of an inflammatory and vascular disease. Clin Neurol Neurosurg. 2017;161:48–50.CrossRefPubMed
56.
Zurück zum Zitat Yeo M, Lee HL, Cha M, Kim JS, Han HS, Lee SH, et al. Neuro-Behcet disease presenting as a solitary cerebellar hemorrhagic lesion: a case report and review of the literature. J Med Case Rep. 2016;10(1):360.CrossRefPubMedPubMedCentral Yeo M, Lee HL, Cha M, Kim JS, Han HS, Lee SH, et al. Neuro-Behcet disease presenting as a solitary cerebellar hemorrhagic lesion: a case report and review of the literature. J Med Case Rep. 2016;10(1):360.CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat Taskapilioglu O, Seferoglu M, Akkaya C, Hakyemez B, Yusufoglu C, Basak AN, et al. Delayed diagnosis of a neuro-Behçet patient with only brainstem and cerebellar atrophy: literature review. J Neurol Sci. 2009;277(1–2):160–3.CrossRefPubMed Taskapilioglu O, Seferoglu M, Akkaya C, Hakyemez B, Yusufoglu C, Basak AN, et al. Delayed diagnosis of a neuro-Behçet patient with only brainstem and cerebellar atrophy: literature review. J Neurol Sci. 2009;277(1–2):160–3.CrossRefPubMed
58.
Zurück zum Zitat Albayram S, Saip S, Hasiloglu ZI, Teke M, Ceyhan E, Tutuncu M, et al. Evaluation of parenchymal neuro-Behçet disease by using susceptibility-weighted imaging. AJNR Am J Neuroradiol. 2011;32(6):1050–5.CrossRefPubMed Albayram S, Saip S, Hasiloglu ZI, Teke M, Ceyhan E, Tutuncu M, et al. Evaluation of parenchymal neuro-Behçet disease by using susceptibility-weighted imaging. AJNR Am J Neuroradiol. 2011;32(6):1050–5.CrossRefPubMed
59.
Zurück zum Zitat Ilhan D, Gulcan E, Uzuner N, Celikkas E. Cerebrovascular manifestations of Behçet’s disease. J Clin Neurosci. 2009;16(4):576–8.CrossRefPubMed Ilhan D, Gulcan E, Uzuner N, Celikkas E. Cerebrovascular manifestations of Behçet’s disease. J Clin Neurosci. 2009;16(4):576–8.CrossRefPubMed
60.
Zurück zum Zitat Coban O, Bahar S, Akman-Demir G, Taşci B, Yurdakul S, Yazici H, et al. Masked assessment of MRI findings: is it possible to differentiate neuro-Behçet’s disease from other central nervous system diseases? Neuroradiology. 1999;41(4):255–60.CrossRefPubMed Coban O, Bahar S, Akman-Demir G, Taşci B, Yurdakul S, Yazici H, et al. Masked assessment of MRI findings: is it possible to differentiate neuro-Behçet’s disease from other central nervous system diseases? Neuroradiology. 1999;41(4):255–60.CrossRefPubMed
61.
Zurück zum Zitat Hirohata S. Histopathology of central nervous system lesions in Behçet’s disease. J Neurol Sci. 2008;267(1–2):41–7.CrossRefPubMed Hirohata S. Histopathology of central nervous system lesions in Behçet’s disease. J Neurol Sci. 2008;267(1–2):41–7.CrossRefPubMed
62.
Zurück zum Zitat •• Uygunoglu U, Zeydan B, Ozguler Y, et al. Myelopathy in Behçet’s disease: the Bagel sign. Ann Neurol. 2017;82(2):288–98. The authors described a new pattern in BS patients presenting with spinal card involvement. This pattern labeled as ‘Bagel sign’. Together with other findings, ‘Bagel sign’ supports the venous theory in BS pathogenesis. CrossRefPubMed •• Uygunoglu U, Zeydan B, Ozguler Y, et al. Myelopathy in Behçet’s disease: the Bagel sign. Ann Neurol. 2017;82(2):288–98. The authors described a new pattern in BS patients presenting with spinal card involvement. This pattern labeled as ‘Bagel sign’. Together with other findings, ‘Bagel sign’ supports the venous theory in BS pathogenesis. CrossRefPubMed
63.
Zurück zum Zitat Lee HS, Kim do Y, Shin HY, Choi YC, Kim SM. Spinal cord involvement in Behcet’s disease. Mult Scler. 2016;22:960–3.CrossRefPubMed Lee HS, Kim do Y, Shin HY, Choi YC, Kim SM. Spinal cord involvement in Behcet’s disease. Mult Scler. 2016;22:960–3.CrossRefPubMed
64.
Zurück zum Zitat Coulter I, Huda S, Baborie A, Jacob A. Longitudinally extensive transverse myelitis as the sole presentation of neuro-Behcet’s disease responding to infliximab. J Spinal Cord Med. 2012;35:122–4.CrossRefPubMedPubMedCentral Coulter I, Huda S, Baborie A, Jacob A. Longitudinally extensive transverse myelitis as the sole presentation of neuro-Behcet’s disease responding to infliximab. J Spinal Cord Med. 2012;35:122–4.CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat Uygunoglu U, Pasha M, Saip S, Siva A. Recurrent longitudinal extensive transverse myelitis in a neuro-Behcet syndrome treated with infliximab. J Spinal Cord Med. 2015;38:111–4.CrossRefPubMedPubMedCentral Uygunoglu U, Pasha M, Saip S, Siva A. Recurrent longitudinal extensive transverse myelitis in a neuro-Behcet syndrome treated with infliximab. J Spinal Cord Med. 2015;38:111–4.CrossRefPubMedPubMedCentral
67.
Zurück zum Zitat Saruhan-Direskeneli G, Yentür SP, Mutlu M, Shugaiv E, Yesilot N, Kürtüncü M, et al. Intrathecal oligoclonal IgG bands are infrequently found in neuro-Behçet’s disease. Clin Exp Rheumatol. 2013;31(3 Suppl 77):25–7.PubMed Saruhan-Direskeneli G, Yentür SP, Mutlu M, Shugaiv E, Yesilot N, Kürtüncü M, et al. Intrathecal oligoclonal IgG bands are infrequently found in neuro-Behçet’s disease. Clin Exp Rheumatol. 2013;31(3 Suppl 77):25–7.PubMed
68.
Zurück zum Zitat Yesilot N, Bahar S, Yilmazer S, Mutlu M, Kurtuncu M, Tuncay R, et al. Cerebral venous thrombosis in Behçet’s disease compared to those associated with other etiologies. J Neurol. 2009;256(7):1134–42.CrossRefPubMed Yesilot N, Bahar S, Yilmazer S, Mutlu M, Kurtuncu M, Tuncay R, et al. Cerebral venous thrombosis in Behçet’s disease compared to those associated with other etiologies. J Neurol. 2009;256(7):1134–42.CrossRefPubMed
69.
Zurück zum Zitat Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications of Behcet’s syndrome. Brain. 1999;122:2183–94.CrossRefPubMed Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications of Behcet’s syndrome. Brain. 1999;122:2183–94.CrossRefPubMed
70.
Zurück zum Zitat Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, et al. Clinical characteristics of neuro-Behcet’s disease in Japan: a multicenter retrospective analysis. Mod Rheumatol. 2012;22(3):405–13.CrossRefPubMed Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, et al. Clinical characteristics of neuro-Behcet’s disease in Japan: a multicenter retrospective analysis. Mod Rheumatol. 2012;22(3):405–13.CrossRefPubMed
71.
Zurück zum Zitat Akman-Demir G, Saip S, Siva A. Behçet’s disease. Curr Treat Options Neurol. 2011;13(3):290–310.CrossRefPubMed Akman-Demir G, Saip S, Siva A. Behçet’s disease. Curr Treat Options Neurol. 2011;13(3):290–310.CrossRefPubMed
72.
Zurück zum Zitat •• Zeydan B, Uygunoglu U, Saip S, Demirci ON, Seyahi E, Ugurlu S, et al. Infliximab is a plausible alternative for neurologic complications of Behçet disease. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e258. The authors observed that patients receiving infliximab did not have any further relapses during treatment. Additionally, none of the patients had neurological involvement while they were receiving infliximab for BS symptoms. CrossRefPubMedPubMedCentral •• Zeydan B, Uygunoglu U, Saip S, Demirci ON, Seyahi E, Ugurlu S, et al. Infliximab is a plausible alternative for neurologic complications of Behçet disease. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e258. The authors observed that patients receiving infliximab did not have any further relapses during treatment. Additionally, none of the patients had neurological involvement while they were receiving infliximab for BS symptoms. CrossRefPubMedPubMedCentral
73.
Zurück zum Zitat Borekci S, Atahan E, Demir Yilmaz D, Mazıcan N, Duman B, Ozguler Y, et al. Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-α treatment. Respiration. 2015;90(3):191–8.CrossRefPubMed Borekci S, Atahan E, Demir Yilmaz D, Mazıcan N, Duman B, Ozguler Y, et al. Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-α treatment. Respiration. 2015;90(3):191–8.CrossRefPubMed
74.
Zurück zum Zitat British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax. 2005;60:800–5.CrossRef British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax. 2005;60:800–5.CrossRef
75.
Zurück zum Zitat Sfikakis PP, Arida A, Panopoulos S, Fragiadaki K, Pentazos G, Laskari K, et al. Brief report: drug-free long-term remission in severe Behçet’s disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheumatol. 2017;69(12):2380–5.CrossRefPubMed Sfikakis PP, Arida A, Panopoulos S, Fragiadaki K, Pentazos G, Laskari K, et al. Brief report: drug-free long-term remission in severe Behçet’s disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheumatol. 2017;69(12):2380–5.CrossRefPubMed
76.
Zurück zum Zitat Murdaca G, Spanò F, Contatore M, Guastalla A, Penza E, Magnani O, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15(1):43–52.CrossRefPubMed Murdaca G, Spanò F, Contatore M, Guastalla A, Penza E, Magnani O, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15(1):43–52.CrossRefPubMed
78.
Zurück zum Zitat Kötter I, Günaydin I, Batra M, Vonthein R, Stübiger N, Fierlbeck G, et al. CNS involvement occurs more frequently in patients with Behcet’s disease under cyclosporin A than under other medications results of a retrospective analysis of 117 cases. Clin Rheumatol. 2006;25:482–6.CrossRefPubMed Kötter I, Günaydin I, Batra M, Vonthein R, Stübiger N, Fierlbeck G, et al. CNS involvement occurs more frequently in patients with Behcet’s disease under cyclosporin A than under other medications results of a retrospective analysis of 117 cases. Clin Rheumatol. 2006;25:482–6.CrossRefPubMed
79.
Zurück zum Zitat Akman-Demir G, Ayranci O, Kurtuncu M, Vanli EN, Mutlu M, Tugal-Tutkun I. Cyclosporine for Behcet’s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol. 2008;26:S84–90.PubMed Akman-Demir G, Ayranci O, Kurtuncu M, Vanli EN, Mutlu M, Tugal-Tutkun I. Cyclosporine for Behcet’s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol. 2008;26:S84–90.PubMed
80.
Zurück zum Zitat Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behcet disease: evolution of clinical manifestations. Medicine (Baltimore). 2011;90:125–32.CrossRef Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behcet disease: evolution of clinical manifestations. Medicine (Baltimore). 2011;90:125–32.CrossRef
81.
Zurück zum Zitat Al-Araji A, Kidd DP. Neuro-Behçet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8(2):192–204.CrossRefPubMed Al-Araji A, Kidd DP. Neuro-Behçet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8(2):192–204.CrossRefPubMed
Metadaten
Titel
Behçet’s Syndrome and Nervous System Involvement
verfasst von
Uğur Uygunoğlu
Aksel Siva
Publikationsdatum
01.07.2018
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 7/2018
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-018-0843-5

Weitere Artikel der Ausgabe 7/2018

Current Neurology and Neuroscience Reports 7/2018 Zur Ausgabe

Demyelinating Disorders (J Bernard and M Cameron, Section Editors)

Caring for Women with Multiple Sclerosis Across the Lifespan

Headache (R Halker, Section Editor)

Women and Migraine: the Role of Hormones

Sleep (M Thorpy and M Billiard, Section Editors)

Narcolepsy Associated with Pandemrix Vaccine

Sleep (M Thorpy and M Billiard, Section Editors)

The Sleep Disorder in Anti-lgLON5 Disease

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.